Mortality in multiple sclerosis: Meta-analysis of standardised mortality ratios

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 3, 2016, Pages 324-331

  Manouchehrinia, Ali ^a   Tanasescu, Radu ^a,b   Tench, Christopher R ^a   Constantinescu, Cris S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; FOLLOW UP; GENDER; HUMAN; INFECTION; LONGITUDINAL STUDY; MORTALITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SUICIDE; CAUSE OF DEATH; FEMALE; MALE; META ANALYSIS; SEX DIFFERENCE;

CAUSE OF DEATH; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; SEX FACTORS;

EID: 84964327230     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-310361     Document Type: Article

References (42)

1. Scalfari A, Knappertz V, Cutter G, et al. Mortality in patients with multiple sclerosis. Neurology 2013;81:184-92.
2. Kingwell E, Marriott JJ, Jetté N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013;13:128.
3. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127(Pt 4):844-50.
4. Kingwell E, van der Kop M, Zhao Y, et al. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry 2012;83:61-6.
5. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 2012;78:1315-22.
6. Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
7. Dever GEA, Champagne F. Epidemiology in health services management. Rockville, Md: Aspen Systems Corporation, 1984.
8. Breslow NE, Day NE. Statistical methods in cancer research. Volume II - the design and analysis of cohort studies. IARC Sci Publ 1987;(82):1-406.
9. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd edn. Philadelphia, Pa.; London: Lippincott Williams & Wilkins, 2008.
10. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
11. Tassinari T, Parodi S, Badino R, et al. Mortality trend for multiple sclerosis in Italy (1974-1993). Eur J Epidemiol 2001;17:105-10.
12. Jick SS, Li L, Falcone GJ, et al. Mortality of patients with multiple sclerosis: a cohort study in UK primary care. J Neurol 2014;261:1508-17.
13. Llorca J, Guerrero P, Prieto-Salceda D, et al. Mortality of multiple sclerosis in Spain: demonstration of a north-South gradient. Neuroepidemiology 2005;24:135-40.
14. Bostrom I, Riise T, Landtblom AM. Mortality statistics for multiple sclerosis and amyotrophic lateral sclerosis in Sweden. Neuroepidemiology 2012;38:245-9.
15. Fredrikson S, Cheng Q, Jiang G-X, et al. Elevated suicide risk among patients with multiple sclerosis in Sweden. Neuroepidemiology 2003;22:146-52.
16. Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4.
17. Van Houten WH, Friede RL. Histochemical studies of experimental demyelination produced with cyanide. Exp Neurol 1961;4:402-12.
18. Wallin MT, Page WF, Kurtzke JF. Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis. Brain 2000;123(Pt 8): 1677-87.
19. Goodin DS, Corwin M, Kaufman D, et al. Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States. PLoS ONE 2014;9:e105207.
20. Hirst C, Swingler R, Compston DAS, et al. Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry 2008;79:1016-21.
21. Lalmohamed A, Bazelier MT, Van Staa TP, et al. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol 2012;19:1007-14.
22. Leray E, Morrissey S, Yaouanq J, et al. Long-term survival of patients with multiple sclerosis in West France. Mult Scler 2007;13:865-74.
23. Smestad C, Sandvik L, Celius EG. Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients. Mult Scler 2009;15:1263-70.
24. Sumelahti M-L, Hakama M, Elovaara I, et al. Causes of death among patients with multiple sclerosis. Mult Scler 2010;16:1437-42.
25. Ragonese P, Aridon P, Mazzola MA, et al. Multiple sclerosis survival: a populationbased study in Sicily. Eur J Neurol 2010;17:391-7.
26. Grytten Torkildsen N, Lie S, Aarseth J, et al. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 2008;14:1191-8.
27. Manouchehrinia A, Weston M, Tench CR, et al. Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. J Neurol Neurosurg Psychiatry 2014;85:1091-5.
28. Rodríguez-Antigüedad Zarranz A, Mendibe Bilbao M, Llarena González C, et al. Mortality and Cause of Death in Multiple Sclerosis: findings from a Prospective Population-Based Cohort in Bizkaia, Basque Country, Spain. Neuroepidemiology 2014;42:219-25.
29. Bronnum-Hansen H, Stenager E, Nylev Stenager E, et al. Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:1457-9.
30. Kingwell E, Evans C, Duggan T, et al. Causes of death in multiple sclerosis patients from British Columbia, Canada. In 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 2012. Lyon, France.
31. Bergamaschi R, Berzuini C, Romani A, et al. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 2001;189:13-21.
32. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland. J Neurol Neurosurg Psychiatry 1987;50:523-31.
33. Ekestern E, Lebhart G. Mortality from multiple sclerosis in Austria 1970-2001: dynamics, trends, and prospects. Eur J Neurol 2004;11:511-20.
34. Celius EG, Smestad C. Change in sex ratio, disease course and age at diagnosis in Oslo MS patients through seven decades. Acta Neurol Scand Suppl 2009; (189):27-9.
35. Tsai CP, Lee CT. Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008. Clin Drug Investig 2013;33:647-52.
36. Mutluay FK, Gurses HN, Saip S. Effects of multiple sclerosis on respiratory functions. Clin Rehabil 2005;19:426-32.
37. Gosselink R, Kovacs L, Ketelaer P, et al. Respiratory muscle weakness and respiratory muscle training in severely disabled multiple sclerosis patients. Arch Phys Med Rehabil 2000;81:747-51.
38. Handel AE, Ramagopalan SV. Multiple sclerosis and risk of cancer: a meta-analysis. J Neurol Neurosurg Psychiatry 2010;81:1413-14.
39. Montgomery S, Hassan A, Bahmanyar S, et al. Mortality following a brain tumour diagnosis in patients with multiple sclerosis. BMJ Open 2013;3:e003622.
40. Wens I, Dalgas U, Stenager E, et al. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis - a systematic review. Mult Scler 2013;19:1556-64.
41. Jadidi E, Mohammadi M, Moradi T. High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler 2013;19:1336-40.
42. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-9.